Publications
Detailed Information
Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Lee, Jae-Ho | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Lee, Choon-Taek | - |
dc.contributor.author | Yoon, Ho Il | - |
dc.date.accessioned | 2012-06-25T08:55:16Z | - |
dc.date.available | 2012-06-25T08:55:16Z | - |
dc.date.issued | 2009-01 | - |
dc.identifier.citation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY; Vol.39 1; 27-32 | ko_KR |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77403 | - |
dc.description.abstract | Pemetrexed has been approved for second-line treatment in non-small cell lung cancer (NSCLC). However, the role of third-line pemetrexed therapy in NSCLC has not yet been generally accepted. We attempted to validate third-line pemetrexed therapy and evaluate predictive factors for pemetrexed therapy for NSCLC. Medical records of NSCLC patients who received pemetrexed therapy that progressed after systemic therapy were reviewed retrospectively. We stratified patients according to clinicopathologic characteristics to find predictive factors for pemetrexed therapy. A total of 100 patients were eligible for analysis, and overall progression-free survival (PFS) was 3.03 months. The objective response rate was 12%, and the toxicity profile was favorable. Pemetrexed was used as a second-line treatment in 30% of patients, and as third- or further-line treatment in 70%. Comparing the efficacy of pemetrexed in these two settings (second-line versus third- or further-line), there was no significant difference in terms of PFS (3.07 versus 2.83 months, P = 0.86). When we evaluated predictive factors by multivariate analysis, performance status significantly influenced PFS. Pemetrexed is a suitable third-line treatment option with good efficacy and tolerable toxicity profile for NSCLC. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | OXFORD UNIV PRESS | ko_KR |
dc.subject | non-small cell lung cancer | ko_KR |
dc.subject | second-line | ko_KR |
dc.subject | third-line | ko_KR |
dc.subject | pemetrexed | ko_KR |
dc.title | Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 선종무 | - |
dc.contributor.AlternativeAuthor | 이근욱 | - |
dc.contributor.AlternativeAuthor | 김지현 | - |
dc.contributor.AlternativeAuthor | 김유정 | - |
dc.contributor.AlternativeAuthor | 윤호일 | - |
dc.contributor.AlternativeAuthor | 이재호 | - |
dc.contributor.AlternativeAuthor | 이춘택 | - |
dc.contributor.AlternativeAuthor | 이종석 | - |
dc.identifier.doi | 10.1093/jjco/hyn118 | - |
dc.citation.journaltitle | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.description.citedreference | Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375 | - |
dc.description.citedreference | Kulkarni PM, 2008, CRIT REV ONCOL HEMAT, V67, P64, DOI 10.1016/j.critrevonc.2008.01.011 | - |
dc.description.citedreference | Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1168/1078-0432.CCR-07-5143 | - |
dc.description.citedreference | Bearz A, 2008, LUNG CANCER, V60, P240, DOI 10.1016/j.lungcan.2007.10.008 | - |
dc.description.citedreference | de Marinisa F, 2008, ONCOLOGIST, V13, P14, DOI 10.1634/theoncologist.13-S1-14 | - |
dc.description.citedreference | CIULEANU TE, 2008, P AM SOC CLIN ONCOL, V26 | - |
dc.description.citedreference | Pujol JL, 2007, J THORAC ONCOL, V2, P397 | - |
dc.description.citedreference | Weiss GJ, 2007, ANN ONCOL, V18, P453, DOI 10.1093/annonc/mdl454 | - |
dc.description.citedreference | Weiss GJ, 2006, J CLIN ONCOL, V24, P4405, DOI 10.1200/JCO.2006.06.7835 | - |
dc.description.citedreference | Murillo JR, 2006, ONCOLOGIST, V11, P1095, DOI 10.1634/theoncologist.11-10-1095 | - |
dc.description.citedreference | Shepherd FA, 2005, NEW ENGL J MED, V353, P123 | - |
dc.description.citedreference | Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163 | - |
dc.description.citedreference | Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S01053-4296(03)00031-6 | - |
dc.description.citedreference | Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55 | - |
dc.description.citedreference | Breathnach OS, 2001, J CLIN ONCOL, V19, P1734 | - |
dc.description.citedreference | Fossella FV, 2000, J CLIN ONCOL, V18, P2354 | - |
dc.description.citedreference | Shepherd FA, 2000, J CLIN ONCOL, V18, P2095 | - |
dc.description.citedreference | Therasse P, 2000, J NATL CANCER I, V92, P205 | - |
dc.description.tc | 13 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.